We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Innoviva (INVA - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Innoviva is one of 892 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. INVA is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for INVA's full-year earnings has moved 17.16% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that INVA has returned about 0.14% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -3.48% on a year-to-date basis. This means that Innoviva is performing better than its sector in terms of year-to-date returns.
To break things down more, INVA belongs to the Large Cap Pharmaceuticals industry, a group that includes 15 individual companies and currently sits at #17 in the Zacks Industry Rank. On average, this group has lost an average of 0.88% so far this year, meaning that INVA is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track INVA. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of Innoviva (INVA - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Innoviva is one of 892 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. INVA is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for INVA's full-year earnings has moved 17.16% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that INVA has returned about 0.14% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -3.48% on a year-to-date basis. This means that Innoviva is performing better than its sector in terms of year-to-date returns.
To break things down more, INVA belongs to the Large Cap Pharmaceuticals industry, a group that includes 15 individual companies and currently sits at #17 in the Zacks Industry Rank. On average, this group has lost an average of 0.88% so far this year, meaning that INVA is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track INVA. The stock will be looking to continue its solid performance.